A large phase I trial offers further evidence that the anti–PD-L1 agent avelumab is generally well tolerated and results in relatively few serious adverse events.
Vemurafenib offered numerical improvement in disease-free survival in patients with resected melanoma, but the results did not reach statistical significance.
Incorporating MRI-based parameters into a risk model could cut down on the number of unnecessary biopsies performed in patients with suspected prostate cancer.
Early-phase data on larotrectinib validate TRK fusions as therapeutic targets and show they lead to tumor-agnostic sensitivity to this agent.
The significant tumor shrinkage and immunologic changes observed support a complementary role of SBRT and PD-1 immunotherapy, investigators concluded.
Circulating tumor DNA can help differentiate pseudoprogression from true progression in patients with melanoma who are treated with PD-1 inhibitors.
Patients with ER-negative, but not ER-positive, isolated locoregional recurrence after unilateral breast cancer derive significant benefit from chemotherapy.
The observed narrowing of racial disparities in prostate cancer outcome since the advent of PSA screening is not as large as previously believed.
Patients with human papillomavirus–associated head and neck cancers who respond well to induction therapy can receive substantially lower doses of radiation and still achieve good safety and efficacy outcomes, according to a new phase II trial.
The addition of metronomic chemotherapy to dual HER2 blockade improved outcomes in older and frail patients with HER2-positive metastatic breast cancer.